CV Sciences (CVSI) Rises 15% As Company Launches new PlusCBD Softgels

CV Sciences (CVSI), a consumer wellness company specializing in hemp extracts and other proven natural ingredients, jumped 15% for the day shortly after announcing the launch of a new product. The Company’s new offering – +PlusCBD™ Reserve Collection Softgels in a 30-count bottle – will be available on their website on Thursday, Jan. 19.

“Consumers have quickly adopted Reserve Softgels into their lifestyles, appreciating the product’s easy-to-take and familiar format as well as its life-enhancing effects,” said Joseph Dowling, CEO of CV Sciences. “Now available in a smaller 30-count bottle, Reserve Softgels are more accessible to a wider range of budgets at an affordable price. We strongly believe that this new addition will encourage more consumers, from the experts to the canna-curious, to leverage cannabis to reduce their depression, stress and anxiety.”

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB: CVSI) is a consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, which are sold through a range of sales channels from B2B to B2C.  The Company’s +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are one of the top-selling brands of hemp extracts in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry.  CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications.  With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

About the Author

CV Sciences (CVSI) Rises 15% As Company Launches new PlusCBD Softgels

Investors Prism